New combo therapy aims to wipe out last traces of blood cancer
NCT ID NCT04501939
Summary
This study tests whether adding the experimental drug cirmtuzumab to standard venetoclax treatment can eliminate the last remaining cancer cells in patients with chronic lymphocytic leukemia (CLL). It involves 5 patients who have been on venetoclax for at least a year but still show detectable cancer. The goal is to see if this combination can achieve undetectable disease levels and delay the need for further treatment.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC LYMPHOCYTIC LEUKEMIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
UCSD Koman Family Outpatient Pavilion
San Diego, California, 92037, United States
Conditions
Explore the condition pages connected to this study.